Vaccinex is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.62 – an increase of 14.56% over the previous week. Vaccinex employs 37 staff and has a trailing 12-month revenue of around $356,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.62 |
|---|---|
| 52-week range | $1.39 - $13.02 |
| 50-day moving average | $3.33 |
| 200-day moving average | $5.79 |
| Wall St. target price | $7.00 |
| PE ratio | 0.4879 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $7.42 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.6 from 2024-11-21
| 1 week (2024-11-15) | 13.92% |
|---|---|
| 1 month (2024-10-24) | 6.19% |
| 3 months (2024-08-23) | -33.09% |
| 6 months (2024-05-23) | -30.10% |
| 1 year (2023-11-22) | 297.97% |
|---|---|
| 2 years (2022-11-23) | -96.36% |
| 3 years (2021-11-23) | 338.1 |
| 5 years (2019-11-22) | 967.386 |
Valuing Vaccinex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vaccinex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vaccinex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Vaccinex shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $356,000 |
|---|---|
| Gross profit TTM | $-13,704,000 |
| Return on assets TTM | -495.64% |
| Return on equity TTM | -759.09% |
| Profit margin | 0% |
| Book value | $-2.59 |
| Market Capitalization | $9.7 million |
TTM: trailing 12 months
We're not expecting Vaccinex to pay a dividend over the next 12 months.
Vaccinex's shares were split on a 1:14 basis on 19 February 2024 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaccinex shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Vaccinex shares which in turn could have impacted Vaccinex's share price.
Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.39 up to $13.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 0.985. This would suggest that Vaccinex's shares are less volatile than average (for this exchange).
Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S. A.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.